SBRT for Breast Cancer: 8 Real Stories

8 stories match breast cancer and SBRT. 7 of them mention surgery.

Cancer Stories

Jennifer, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Jennifer's Patient Story

Patient Info: Jennifer Feinberg, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain

8+ years after her initial breast cancer diagnosis, she was living with metastatic HER2-positive breast cancer with brain metastases and receiving trastuzumab as her tenth line of treatment.

Dana-Farber
OutcomeLiving With Cancer
Shari, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient Story
OutcomeLiving With Cancer / Ongoing Therapy
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Local Breast Cancer Recurrence Was Found During BioZorb Surveillance

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial right breast tumor: ER-positive, PR-positive, HER2-equivocal. Recurrent right breast tumor: ER-positive, HER2-negative.

Two sites of right-breast recurrence were confirmed three years after lumpectomy, leading to right mastectomy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Recurrence Treated With Radiation Despite a Chronic Skin Condition

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative

After treatment of a chest-wall recurrence and a radiographically suspicious ischial lesion, she completed chest-wall radiation, her skin healed within 5 weeks, and she remained under surgical, radiation-oncology, and dermatology review.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-Positive Recurrent Breast Cancer Treated With Multiple Targeted and Local Therapies

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: 2008 recurrence: ER 80%, HER2 FISH amplified. 2011 recurrence: ER 80%

Metastatic Site: liver, skin

After 25 cycles of eribulin, treatment was still ongoing; nodal disease remained stable, while later imaging also noted new metabolic activity in the upper lung.

PubMed Central
OutcomeCare Ongoing